[China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020

Announced Date: 2025-06-22 (June 22, 2025)

Asset Name: HBM7020

Licensor (Seller): Harbour BioMed (China)

Licensee (Buyer): Otsuka Pharmaceutical（Japan）

.

Asset Modality: bispecific antibody, T cell-engager (TCE),

Asset Target: BCMAxCD3 

Potential Indication: autoimmune diseases, cancer

Stage until the deal: Phase I in China

.

Scope of Authority:

Otsuka is granted an exclusive license to develop, manufacture, and commercialize HBM7020, a BCMAxCD3 bispecific T-cell engager globally, excluding Greater China (Mainland China, Hong Kong, Macau and Taiwan).

.

Payment Detail:

Harbour BioMed will receive

Upfront and near-term payments US$47 million, .

Development and commercial milestonesup to US$623 million.

Tiered royalties on future net sales.

.

Link:

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers-HBM Holdings

.

Note:

Chinese Name of “Harbour BioMed“, “和铂医药”